Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Clinical Study to Assess the Efficacy and Safety of SC-101 in Patients With Advanced Malignant Tumors Positive for NECTIN4 Gene Amplification

NCT07080619 is registered in ClinicalTrials.gov with Tianjin ConjuStar Biologics Co., Ltd. as lead sponsor.

NCT NCT07080619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07080619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Clinical Study to Assess the Efficacy and Safety of SC-101 in Patients With Advanced Malignant Tumors Positive for NECTIN4 Gene Amplification
Lead sponsor
Tianjin ConjuStar Biologics Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 20, 2025
Completion date
December 30, 2027
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hr+ breast cancer, tnbc - triple-negative breast cancer